Dianna Kageni Mbari-Fondo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dianna Kageni Mbari-Fondo has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Japheth Mativo Nzioki
Andrews University, Berrien Springs, Michigan, USA
3 shared publications - John Kyalo Muthuka
Kenya Medical Training College
3 shared publications - Kelly Oluoch
Kenya Medical Training College (KMTC), Nairobi, Kenya
3 shared publications Everlyn Musangi Nyamai
2 shared publications- Francis Muchiri Wambura
Kenya Medical Training College, Nairobi, Kenya
2 shared publications - Rosemary Nabaweesi
Meharry Medical College
2 shared publications
Latest Publications
- Open Access
Effectiveness and Types of Interventions for Autism Spectrum Disorder: A Systematic Review and Meta-Analysis
This systematic review and meta-analysis aimed to estimate the overall effectiveness of ASD interventions and identify sources of heterogeneity using frequentist and Bayesian approaches. A systematic search of PubMed/MEDLINE, Embase, Web of Science, and Scopus was conducted for studies published between January 1, 2004, and April 30, 2025. Mainly, randomized controlled trial studies with extractable intervention outcomes were included. A total of 41 studies (n=3,008) were synthesized using random-effects models (REML), Bayesian hierarchical modeling, meta-regression, and sensitivity analyses following PRISMA guidelines. The pooled random-effects estimate showed a significant positive effect of ASD interventions (effect size = 0.506, 95% CI: 0.392–0.619; z = 8.72, p < .001), corresponding to an estimated success proportion of 62% (95% CI: 59%–65%). Heterogeneity was substantial (Q□(40) = 238.78, p < .001; I² = 82.45%; τ² = 0.069, 95% CI: 0.028–0.137; τ = 0.262), with H² = 5.70 and a wide prediction interval (−0.020 to 1.031), indicating strong between-study variability. Bayesian meta-analysis confirmed a comparable effect (posterior mean = 0.619, 95% CrI: 0.592–0.646), with τ = 0.273 and I² ≈ 82.5%, and MCMC diagnostics showed stable convergence (R-hat ≈ 1.00). Publication bias analyses indicated significant funnel plot asymmetry (Egger-type regression: z = 3.429, p < .001; weighted regression: t = 9.573, p < .001), while rank correlation was non-significant (τ = −0.178, p = .103). Trim-and-fill analysis imputed 10 studies, reducing the pooled effect to 0.374 (95% CI: 0.258–0.491; τ = 0.338), though the effect remained significant (p < .001). Sensitivity analyses excluding influential studies yielded a stable effect (0.505, 95% CI: 0.401–0.609), with persistent heterogeneity (I² = 75.49%; Q□(38) = 190.21, p < .001; τ² = 0.043). Subgroup analyses showed highest effects for digital/technology-based interventions (0.672; 67%; I² = 0%), followed by nutritional (0.635; 64%; I² = 73.81%), behavioral (0.630; 63%; I² = 74.78%), and pharmacological (0.627; 63%; I² = 0%) interventions, while physical/occupational therapies showed lower effects (0.523; 52%; I² = 63.35%) and combined interventions showed borderline effects (0.593; 59%; I² = 19.96%); subgroup differences were significant (Q□5) = 22.63, p < .001). Regional effects were similar and non-significant (Q□(2) = 0.73, p = .694): North America (0.619; I² = 84.21%), Europe (0.626; I² = 62.34%), and Asia (0.659; I² = 0%). Age at intervention onset did not significantly moderate effects (Q□(5) = 0.98, p = .964), although variability was observed across children, adolescents, adults, and toddlers. Meta-regression identified significant moderators including intervention context (Q□= 18.159, p = .020), outcome domain (Q□= 19.588, p = .003), age at start (Q□= 17.795, p = .003), and intervention category (Q□= 31.714, p < .001), while follow-up duration and intervention duration were not significant. Bayesian subgroup analyses confirmed robustness, with strongest evidence for pharmacological (BF → ∞), behavioral (BF ≈ 832.50), and digital interventions (BF ≈ 30.92). In conclusion, ASD interventions demonstrate a moderate and statistically significant overall effect (∼0.50–0.62), with substantial heterogeneity driven primarily by intervention type, context, and participant characteristics, and findings were consistent across frequentist, Bayesian, and sensitivity analyses, supporting robust but context-dependent effectiveness.
Open AccessEffectiveness and Types of Interventions for Autism Spectrum Disorder: A Systematic Review and Meta-Analysis
This systematic review and meta-analysis aimed to estimate the overall effectiveness of ASD interventions and identify sources of heterogeneity using frequentist and Bayesian approaches. A systematic search of PubMed/MEDLINE, Embase, Web of Science, and Scopus was conducted for studies published between January 1, 2004, and April 30, 2025. Mainly, randomized controlled trial studies with extractable intervention outcomes were included. A total of 41 studies (n=3,008) were synthesized using random-effects models (REML), Bayesian hierarchical modeling, meta-regression, and sensitivity analyses following PRISMA guidelines. The pooled random-effects estimate showed a significant positive effect of ASD interventions (effect size = 0.506, 95% CI: 0.392–0.619; z = 8.72, p < .001), corresponding to an estimated success proportion of 62% (95% CI: 59%–65%). Heterogeneity was substantial (Q□(40) = 238.78, p < .001; I² = 82.45%; τ² = 0.069, 95% CI: 0.028–0.137; τ = 0.262), with H² = 5.70 and a wide prediction interval (−0.020 to 1.031), indicating strong between-study variability. Bayesian meta-analysis confirmed a comparable effect (posterior mean = 0.619, 95% CrI: 0.592–0.646), with τ = 0.273 and I² ≈ 82.5%, and MCMC diagnostics showed stable convergence (R-hat ≈ 1.00). Publication bias analyses indicated significant funnel plot asymmetry (Egger-type regression: z = 3.429, p < .001; weighted regression: t = 9.573, p < .001), while rank correlation was non-significant (τ = −0.178, p = .103). Trim-and-fill analysis imputed 10 studies, reducing the pooled effect to 0.374 (95% CI: 0.258–0.491; τ = 0.338), though the effect remained significant (p < .001). Sensitivity analyses excluding influential studies yielded a stable effect (0.505, 95% CI: 0.401–0.609), with persistent heterogeneity (I² = 75.49%; Q□(38) = 190.21, p < .001; τ² = 0.043). Subgroup analyses showed highest effects for digital/technology-based interventions (0.672; 67%; I² = 0%), followed by nutritional (0.635; 64%; I² = 73.81%), behavioral (0.630; 63%; I² = 74.78%), and pharmacological (0.627; 63%; I² = 0%) interventions, while physical/occupational therapies showed lower effects (0.523; 52%; I² = 63.35%) and combined interventions showed borderline effects (0.593; 59%; I² = 19.96%); subgroup differences were significant (Q□5) = 22.63, p < .001). Regional effects were similar and non-significant (Q□(2) = 0.73, p = .694): North America (0.619; I² = 84.21%), Europe (0.626; I² = 62.34%), and Asia (0.659; I² = 0%). Age at intervention onset did not significantly moderate effects (Q□(5) = 0.98, p = .964), although variability was observed across children, adolescents, adults, and toddlers. Meta-regression identified significant moderators including intervention context (Q□= 18.159, p = .020), outcome domain (Q□= 19.588, p = .003), age at start (Q□= 17.795, p = .003), and intervention category (Q□= 31.714, p < .001), while follow-up duration and intervention duration were not significant. Bayesian subgroup analyses confirmed robustness, with strongest evidence for pharmacological (BF → ∞), behavioral (BF ≈ 832.50), and digital interventions (BF ≈ 30.92). In conclusion, ASD interventions demonstrate a moderate and statistically significant overall effect (∼0.50–0.62), with substantial heterogeneity driven primarily by intervention type, context, and participant characteristics, and findings were consistent across frequentist, Bayesian, and sensitivity analyses, supporting robust but context-dependent effectiveness.
- Open Access
- 6 October 2025
- Published by JMIR Publications Inc. in JMIRx Med
- Vol. 6 (1) , e81711
Authors’ Response to Peer Reviews of “Effects of Interventions for the Prevention and Management of Maternal Anemia in the Advent of the COVID-19 Pandemic: Systematic Review and Meta-Analysis”
This is the author(s)' response to peer review reports related to "Authors’ Response to Peer Reviews of “Effect of and Interventions in Prevention and Management of Maternal Anemia in the Advent of COVID-19 Pandemic: Systematic Review and Meta-Analysis"
- 6 October 2025
- Published by JMIR Publications Inc. in JMIRx Med
- Vol. 6 (1) , e81711
Open AccessAuthors’ Response to Peer Reviews of “Effects of Interventions for the Prevention and Management of Maternal Anemia in the Advent of the COVID-19 Pandemic: Systematic Review and Meta-Analysis”
This is the author(s)' response to peer review reports related to "Authors’ Response to Peer Reviews of “Effect of and Interventions in Prevention and Management of Maternal Anemia in the Advent of COVID-19 Pandemic: Systematic Review and Meta-Analysis"
- Open Access
- 6 October 2025
- Published by JMIR Publications Inc. in JMIRx Med
- Vol. 6 (1) , e57626
Effects of Interventions for the Prevention and Management of Maternal Anemia in the Advent of the COVID-19 Pandemic: Systematic Review and Meta-Analysis
Background: The COVID-19 pandemic presented many unknowns for pregnant women, with anemia potentially worsening pregnancy outcomes due to multiple factors. Objective: This review aimed to determine the pooled effect of maternal anemia interventions and associated factors during the pandemic. Methods: Eligible studies were observational and included reproductive-age women receiving anemia-related interventions during the COVID-19 pandemic. Exclusion criteria comprised non-English publications, reviews, editorials, case reports, studies with insufficient data, sample sizes below 50, and those lacking DOIs. A systematic search of PubMed, Scopus, Embase, Web of Science, and Google Scholar identified articles published between December 2019 and August 2022. Risk of bias was evaluated using the Cochrane Risk of Bias 2 tool for randomized trials and the National Institutes of Health’s assessment tool for observational studies. Pooled rate ratios (RRs) with 95% CIs were calculated in Review Manager 5.4.1. Synthesis included subgroup analysis, meta-regression, and publication bias checks to assess intervention effectiveness. Results: This meta-analysis included 11 studies with 6129 pregnant women. Of these, 3591 (59%) were in the intervention group and 2538 (41%) were in the comparator group. Effects were recorded for 1921 (53.4%) women in the intervention group and 1350 (53.1%) in the comparator group. The cumulative impact ranged from 23% to 81%, averaging 56%. The initial analysis showed no significant effect on anemia prevention (RR 0.79, 95% CI 0.61‐1.02; P =.07), with high heterogeneity ( I ²=97%). Sensitivity analysis excluding 4 outlier studies improved the effect size to a significant level at 39% (RR 0.61, 95% CI 0.43‐0.87; P =.006). Subgroup analysis revealed substantial heterogeneity ( I ²=87.2%). Intravenous sucrose had a poor impact (RR 1.31, 95% CI 1.17‐1.47; P <.001), while medicinal or herbal interventions showed benefit (RR 0.81, 95% CI 0.73‐0.90; P =.006). Educational interventions yielded a 28% effect (RR 0.72), medicinal administration 19% (RR 0.81), iron supplementation 17% (RR 0.83), and intravenous ferric carboxylmaltose 15% (RR 0.85; P <.02). Additional sensitivity analysis confirmed a pooled positive effect of 17% (RR 0.83, 95% CI 0.79‐0.88; P <.001), with minimal heterogeneity ( I ²=0%). Regionally, effectiveness was highest in Africa (RR 0.84, 95% CI 0.79‐0.89; P <.001). Multicenter studies and those with 2020 data were predictive of better outcomes (RR 0.84 and RR 0.50, respectively). Despite initial heterogeneity and publication bias, interventions showed utility in mitigating maternal anemia in targeted subgroups and regions. Conclusions: Maternal anemia interventions during the COVID-19 pandemic showed modest, context-specific effectiveness, with declining impact from 2020 to 2022. Although high heterogeneity and study inconsistencies limited generalizability, significant benefits were observed particularly in African and multicenter studies. The pandemic exposed gaps in maternal health systems, emphasizing the need for tailored interventions, stronger data infrastructure, and resilient care strategies in future global crises.
- 6 October 2025
- Published by JMIR Publications Inc. in JMIRx Med
- Vol. 6 (1) , e57626
Open AccessEffects of Interventions for the Prevention and Management of Maternal Anemia in the Advent of the COVID-19 Pandemic: Systematic Review and Meta-Analysis
Background: The COVID-19 pandemic presented many unknowns for pregnant women, with anemia potentially worsening pregnancy outcomes due to multiple factors. Objective: This review aimed to determine the pooled effect of maternal anemia interventions and associated factors during the pandemic. Methods: Eligible studies were observational and included reproductive-age women receiving anemia-related interventions during the COVID-19 pandemic. Exclusion criteria comprised non-English publications, reviews, editorials, case reports, studies with insufficient data, sample sizes below 50, and those lacking DOIs. A systematic search of PubMed, Scopus, Embase, Web of Science, and Google Scholar identified articles published between December 2019 and August 2022. Risk of bias was evaluated using the Cochrane Risk of Bias 2 tool for randomized trials and the National Institutes of Health’s assessment tool for observational studies. Pooled rate ratios (RRs) with 95% CIs were calculated in Review Manager 5.4.1. Synthesis included subgroup analysis, meta-regression, and publication bias checks to assess intervention effectiveness. Results: This meta-analysis included 11 studies with 6129 pregnant women. Of these, 3591 (59%) were in the intervention group and 2538 (41%) were in the comparator group. Effects were recorded for 1921 (53.4%) women in the intervention group and 1350 (53.1%) in the comparator group. The cumulative impact ranged from 23% to 81%, averaging 56%. The initial analysis showed no significant effect on anemia prevention (RR 0.79, 95% CI 0.61‐1.02; P =.07), with high heterogeneity ( I ²=97%). Sensitivity analysis excluding 4 outlier studies improved the effect size to a significant level at 39% (RR 0.61, 95% CI 0.43‐0.87; P =.006). Subgroup analysis revealed substantial heterogeneity ( I ²=87.2%). Intravenous sucrose had a poor impact (RR 1.31, 95% CI 1.17‐1.47; P <.001), while medicinal or herbal interventions showed benefit (RR 0.81, 95% CI 0.73‐0.90; P =.006). Educational interventions yielded a 28% effect (RR 0.72), medicinal administration 19% (RR 0.81), iron supplementation 17% (RR 0.83), and intravenous ferric carboxylmaltose 15% (RR 0.85; P <.02). Additional sensitivity analysis confirmed a pooled positive effect of 17% (RR 0.83, 95% CI 0.79‐0.88; P <.001), with minimal heterogeneity ( I ²=0%). Regionally, effectiveness was highest in Africa (RR 0.84, 95% CI 0.79‐0.89; P <.001). Multicenter studies and those with 2020 data were predictive of better outcomes (RR 0.84 and RR 0.50, respectively). Despite initial heterogeneity and publication bias, interventions showed utility in mitigating maternal anemia in targeted subgroups and regions. Conclusions: Maternal anemia interventions during the COVID-19 pandemic showed modest, context-specific effectiveness, with declining impact from 2020 to 2022. Although high heterogeneity and study inconsistencies limited generalizability, significant benefits were observed particularly in African and multicenter studies. The pandemic exposed gaps in maternal health systems, emphasizing the need for tailored interventions, stronger data infrastructure, and resilient care strategies in future global crises.